ALB and lung carcinoma: In lung cancer patients, Yin et al. found that combining low albumin (< 35 g/L) with decreased muscle mass effectively distinguished prognostic subgroups, with a median survival gap of up to 9 months (P < 0.001), supporting its use in personalized nutrition-prognosis models (59).